Trust Company of Vermont’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $226K | Buy |
+1,426
| New | +$193K | 0.01% | 353 |
|
|
2025
Q4 | $156K | Buy |
1,276
+348
| +38% | +$39.9K | 0.01% | 390 |
|
|
2025
Q3 | $93K | Sell |
928
-45
| -5% | -$4.05K | ﹤0.01% | 463 |
|
|
2025
Q2 | $80.7K | Sell |
973
-1,660
| -63% | -$132K | ﹤0.01% | 476 |
|
|
2025
Q1 | $214K | Sell |
2,633
-50
| -2% | -$4.47K | 0.01% | 332 |
|
|
2024
Q4 | $242K | Sell |
2,683
-375
| -12% | -$36.3K | 0.01% | 320 |
|
|
2024
Q3 | $302K | Buy |
3,058
+138
| +5% | +$13.6K | 0.02% | 288 |
|
|
2024
Q2 | $271K | Hold |
2,920
| – | – | 0.01% | 284 |
|
|
2024
Q1 | $277K | Buy |
2,920
+875
| +43% | +$81.2K | 0.02% | 277 |
|
|
2023
Q4 | $183K | Sell |
2,045
-1,065
| -34% | -$79.1K | 0.01% | 288 |
|
|
2023
Q3 | $227K | Sell |
3,110
-233
| -7% | -$18.6K | 0.02% | 285 |
|
|
2023
Q2 | $278K | Sell |
3,343
-530
| -14% | -$44.3K | 0.02% | 277 |
|
|
2023
Q1 | $295K | Sell |
3,873
-60
| -2% | -$4.98K | 0.02% | 270 |
|
|
2022
Q4 | $326K | Sell |
3,933
-936
| -19% | -$75.8K | 0.02% | 251 |
|
|
2022
Q3 | $386K | Sell |
4,869
-407
| -8% | -$34.3K | 0.03% | 231 |
|
|
2022
Q2 | $392K | Sell |
5,276
-786
| -13% | -$59K | 0.03% | 234 |
|
|
2022
Q1 | $545K | Hold |
6,062
| – | – | 0.04% | 217 |
|
|
2021
Q4 | $679K | Hold |
6,062
| – | – | 0.04% | 203 |
|
|
2021
Q3 | $762K | Sell |
6,062
-65
| -1% | -$8.37K | 0.05% | 184 |
|
|
2021
Q2 | $830K | Buy |
6,127
+9
| +0.1% | +$1.18K | 0.06% | 180 |
|
|
2021
Q1 | $830K | Sell |
6,118
-240
| -4% | -$35.9K | 0.06% | 174 |
|
|
2020
Q4 | $895K | Buy |
6,358
+178
| +3% | +$22.8K | 0.07% | 166 |
|
|
2020
Q3 | $689K | Buy |
6,180
+39
| +0.6% | +$4.37K | 0.06% | 172 |
|
|
2020
Q2 | $687K | Sell |
6,141
-4,895
| -44% | -$482K | 0.07% | 172 |
|
|
2020
Q1 | $855K | Sell |
11,036
-137
| -1% | -$12.1K | 0.08% | 165 |
|
|
2019
Q4 | $1.06M | Buy |
11,173
+304
| +3% | +$26.3K | 0.08% | 166 |
|
|
2019
Q3 | $829K | Buy |
10,869
+4,059
| +60% | +$337K | 0.07% | 188 |
|
|
2019
Q2 | $597K | Buy |
6,810
+856
| +14% | +$73K | 0.05% | 208 |
|
|
2019
Q1 | $539K | Buy |
5,954
+3,421
| +135% | +$291K | 0.05% | 209 |
|
|
2018
Q4 | $182K | Buy |
2,533
+255
| +11% | +$20.5K | 0.02% | 308 |
|
|
2018
Q3 | $218K | Buy |
2,278
+850
| +60% | +$82.4K | 0.02% | 308 |
|
|
2018
Q2 | $136K | Buy |
+1,428
| New | +$131K | 0.01% | 380 |
|
|
2016
Q1 | – | Sell |
-245
| Closed | -$17K | – | 786 |
|
|
2015
Q4 | $17K | Buy |
245
+50
| +26% | +$3.41K | ﹤0.01% | 562 |
|
|
2015
Q3 | $12K | Buy |
+195
| New | +$15.4K | ﹤0.01% | 610 |
|
Other funds holding XBI
MIH
MSR
PR
SO
WT
Trust Company of Vermont's XBI Position: Q2 2026 in Review
Trust Company of Vermont opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q2 2026: 1,426 shares worth $226K. The stake represents 0.01% of the portfolio and ranks #353 among its holdings. This is a return to the name: Trust Company of Vermont previously reported a position in XBI as recently as Q4 2025.
Trust Company of Vermont first reported a position in XBI in Q3 2015 and has held it in 34 quarters since. The position peaked at $1.06M in Q4 2019. 543 funds tracked by Wall St. Rank hold XBI as of Q2 2026.
- Trust Company of Vermont held 1,426 shares of State Street SPDR S&P Biotech ETF worth $226K as of Q2 2026.
- State Street SPDR S&P Biotech ETF was a new Trust Company of Vermont position in Q2 2026.
- State Street SPDR S&P Biotech ETF made up 0.01% of Trust Company of Vermont's portfolio in Q2 2026, its #353 holding.
- Trust Company of Vermont first reported a position in State Street SPDR S&P Biotech ETF in Q3 2015 and has held it in 34 quarters since.
- Trust Company of Vermont's State Street SPDR S&P Biotech ETF position peaked at $1.06M in Q4 2019.
- 543 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.
Based on Trust Company of Vermont's 13F filing for Q2 2026, filed 7 Aug 2026.